Abstract
Despite their toxicity, the aminoglycosides remain useful and are often the first choice in the treatment of serious infections due to gram-negative bacilli. Nephrotoxicity has restricted the indications for neomycin to topical and oral use. Emergence of resistant organisms has limited the use of streptomycin to a few specific conditions. Gentamicin, tobramycin, and amikacin are effective against a broad spectrum of gram-negative bacilli including Pseudomonas aeruginosa. Amikacin is the aminoglycoside of choice when gentamicin resistance is prevalent.
MeSH terms
-
Amikacin / adverse effects
-
Amikacin / therapeutic use
-
Aminoglycosides / adverse effects
-
Aminoglycosides / therapeutic use
-
Anti-Bacterial Agents / adverse effects
-
Anti-Bacterial Agents / therapeutic use*
-
Bacterial Infections / drug therapy*
-
Gentamicins / adverse effects
-
Gentamicins / therapeutic use
-
Humans
-
Kanamycin / adverse effects
-
Kanamycin / therapeutic use
-
Microbial Sensitivity Tests
-
Netilmicin / adverse effects
-
Netilmicin / therapeutic use
-
Sisomicin / adverse effects
-
Sisomicin / therapeutic use
-
Streptomycin / adverse effects
-
Streptomycin / therapeutic use
-
Tobramycin / adverse effects
-
Tobramycin / therapeutic use
Substances
-
Aminoglycosides
-
Anti-Bacterial Agents
-
Gentamicins
-
Netilmicin
-
Kanamycin
-
Amikacin
-
Tobramycin
-
Sisomicin
-
Streptomycin